• Follow the Money: Migraine Therapy, Reducing Trial Failure, More

    Clinical Research News | Salvia plans to further develop MySalvia Therapy in a multi-center, double-blind, sham-controlled study for people with chronic migraine; Vivodyne plans to scale its robotics+AI approach to testing on thousands of lab-grown, fully-functional human tissues, which aim to reduce human clinical trial failure; and more.

    Jun 25, 2025

  • Veeva, Sarah Cannon Research Institute Collaboration, City of Hope Receives Grant, More

    Clinical Research News | Veeva and Sarah Cannon Research Institute has entered a strategic collaboration; City of Hope was awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the US Department of Health and Human Services; and more.

    Jun 24, 2025

  • Beyond Vitals: How Patient-Generated Data is Driving AI’s Healthcare Transformation

    Clinical Research News | In recent years, AI in healthcare has attracted growing interest and investment, with new roles like Chief AI Officer and AI-specific policies underscoring its transformative potential. However, one critical factor is often overlooked: the quality of the data used to train AI algorithms. While AI’s impact is undeniable, its effectiveness depends on the depth, diversity, and granularity of the data it processes.

    Jun 20, 2025

  • Genetic Testing Transforms Medication Prescribing for Better Patient Outcomes

    Clinical Research News | The UK National Health Service’s PROGRESS trial has achieved remarkable clinical success, with one in four patients having their prescriptions adjusted based on genetic test results, leading to safer and more effective treatments. The PROGRESS trial’s interim results reveal that 95% of the 500 patients tested carried genetic variants that directly influence how they metabolize common medications.

    Jun 18, 2025

  • AI Agent Speeds Up Trials with Instant, Personalized Participant Interactions

    Clinical Research News | An artificial intelligence (AI) agent known as Grace is bringing clinical trials some much-needed speed and cost reduction and delivering more personalized, on-demand digital experiences for participants. Developed by fast-growing Grove AI, Grace has over the past year powered more than 50 phase 2 and 3 trials involving over 500,000 interactions with would-be and enrolled trial participants.

    Jun 17, 2025